nach oben

Erschienen in:

12.07.2020 | Original Article

Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness

verfasst von: Maliheh Ghadir, Mohammad E. Khamseh, Mahshid Panahi-shamsabad, Mohammad Ghorbani, Hamideh Akbari, Ali Zare Mehrjardi, Maryam Honardoost, Bahram Jafar-Mohammadi

Erschienen in: Endocrine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Non-functioning pituitary adenoma (NFPA) is the most prevalent pituitary macroadenoma. No prognostic marker has been found to explain the behavior of these tumors. We aimed to explore cell proliferation, apoptosis, proangiogenic markers, and microvascular density (MVD) in noninvasive and invasive NFPAs.

Methods

Adenoma invasiveness was defined according to Knosp and Hardy classifications based on preoperative magnetic resonance imaging scans. Cell proliferation was examined using Ki67 and P53. Tissue expression of Bcl-2 was used to assess the antiapoptosis pathway. CD34 and CD105 were measured to evaluate MVD, while VEGF expression was assessed as an indicator of pro-angiogenesis. Moreover, VEGF, bFGF, endocan, and endostatin were measured on preoperative serum samples.

Results

Tissue and serum markers were examined in 18 patients with invasive and 21 patients with noninvasive NFPAs. Ki67 less than 3% was reported in 10 invasive and 14 noninvasive NFPAs (P = 0.752). P53 staining was negative in all subjects. In addition, Bcl-2 staining was negative in 15 and 20 subjects, respectively (P = 0.718). VEGF-A expression 2+ or 3+ was reported in 9 invasive and 11 noninvasive macroadenomas (P = 0.83). Moreover, CD34 and CD105 positivity were comparable between the two groups. Furthermore, the comparison of serum markers showed no significant differences.

Conclusion

Cell proliferation, apoptosis, and angiogenesis play a limited role in NFPA behavior.

Nur mit Berechtigung zugänglich

M. Mercado, V. Melgar, L. Salame, D. Cuenca, Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects. Endocrinologia, diabetes y nutricion 64(7), 384–395 (2017)PubMed

M.M. Fernández-Balsells, M.H. Murad, A. Barwise, J.F. Gallegos-Orozco, A. Paul, M.A. Lane, J.F. Lampropulos, I. Natividad, L. Perestelo-Perez, P.G. Ponce de Leon-Lovaton, Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J. Clin. Endocrinol. Metabol. 96(4), 905–912 (2011)

Y. Miao, M. Zong, T. Jiang, X. Yuan, S. Guan, Y. Wang, D. Zhou, A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion. Pituitary 19(2), 194–201 (2016)PubMedPubMedCentral

M.E. Molitch, Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5), 516–524 (2017)PubMed

G. Ntali, J.A. Wass, Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary 21(2), 111–118 (2018)PubMed

A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72(3), 377–382 (2010)

M. Sato, R. Tamura, H. Tamura, T. Mase, K. Kosugi, Y. Morimoto, K. Yoshida, M. Toda, Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J. Clin. Med. 8(5), 695 (2019)PubMedCentral

H. Turner, Z. Nagy, K. Gatter, M. Esiri, J. Wass, A. Harris, Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br. J. Cancer 82(8), 1441–1445 (2000)PubMedPubMedCentral

T.-W. Noh, H.J. Jeong, M.-K. Lee, T.S. Kim, S.H. Kim, E.J. Lee, Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 94(11), 4406–4413 (2009)PubMed

10.

A. Di Ieva, A. Weckman, J. Di Michele, F. Rotondo, F. Grizzi, K. Kovacs, M.D. Cusimano, Microvascular morphometrics of the hypophysis and pituitary tumors: from bench to operating theatre. Microvasc. Res. 89, 7–14 (2013)PubMed

11.

C. Cristina, G.M. Luque, G. Demarchi, F.L. Vicchi, L. Zubeldia-Brenner, M.I.P. Millan, S. Perrone, A.M. Ornstein, I.M. Lacau-Mengido, S.I. Berner, D. Becu-Villalobos, Angiogenesis in pituitary adenomas: human studies and new mutant mouse models. Int. J. Endocrinol. 2014, 1–11 (2014)

12.

M. Niveiro, F.I. Aranda, G. Peiró, C. Alenda, A. Picó, Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum. Pathol. 36(10), 1090–1095 (2005)PubMed

13.

A. Cornelius, C. Cortet‐Rudelli, R. Assaker, O. Kerdraon, M.H. Gevaert, V. Prévot, P. Lassalle, J. Trouillas, M. Delehedde, C.A. Maurage, Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 22(6), 757–764 (2012)PubMed

14.

C. Cristina, M.I. Perez-Millan, G. Luque, R.A. Dulce, G. Sevlever, S.I. Berner, D. Becu-Villalobos, VEGF and CD31 association in pituitary adenomas. Endocr. Pathol. 21(3), 154–160 (2010)PubMed

15.

K.-M. Lee, S.-H. Park, K.-S. Park, J.-H. Hwang, S.-K. Hwang, Analysis of circulating endostatin and vascular endothelial growth factor in patients with pituitary adenoma treated by stereotactic radiosurgery: a preliminary study. Brain Tumor Res. Treat. 3(2), 89–94 (2015)PubMedPubMedCentral

16.

F. Grimm, R. Maurus, R. Beschorner, G. Naros, M. Stanojevic, I. Gugel, S. Giese, G. Bier, B. Bender, J. Honegger, Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Acta Neurochirurgica 161(6), 1149–1156 (2019)PubMed

17.

O. Mete, M.B. Lopes, Overview of the 2017 WHO classification of pituitary tumors. Endocr. Pathol. 28(3), 228–243 (2017)PubMed

18.

N. Weidner, J.P. Semple, W.R. Welch, J. Folkman, Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. New Engl. J. Med. 324(1), 1–8 (1991)PubMed

19.

I.-M. Moldovan, S. Şuşman, R. Pirlog, E.M. Jianu, D.C. Leucuţa, C.S. Melincovici, D. Crişan, I.Ş. Florian, Molecular markers in the diagnosis of invasive pituitary adenomas–an immunohistochemistry study. Rom. J. Morphol. Embryol. 58(4), 1357–1364 (2017)PubMed

20.

E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 33(4), 610–618 (1993)PubMed

21.

J. Hardy, Transphenoidal microsurgical treatment of pituitary. In: J.A. Linfoot (ed.) Recent advances in the diagnosis and treatment of pituitary tumors. (Raven press, New York, 1979), pp. 375–378

22.

K. Kovacs, Tumors of the pituitary gland. Atlas Tumor Pathol Fascicle 21, 1–269 (1986). 2nd series

23.

B.M. Davies, E. Carr, C. Soh, K.K. Gnanalingham, Assessing size of pituitary adenomas: a comparison of qualitative and quantitative methods on MR. Acta Neurochirurgica 158(4), 677–683 (2016)PubMedPubMedCentral

24.

G. Raverot, P. Burman, A. McCormack, A. Heaney, S. Petersenn, V. Popovic, J. Trouillas, O.M. Dekkers, European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178(1), G1–G24 (2018)PubMed

25.

J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.-F. Bonneville, R. Assaker, C. Auger, T. Brue, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126(1), 123–135 (2013)PubMed

26.

Glebauskiene, B., Liutkeviciene, R., Vilkeviciute, A., Gudinaviciene, I., Rocyte, A., Simonaviciute, D., Mazetyte, R., Kriauciuniene, L., Zaliuniene, D. Association of Ki-67 labelling index and IL-17A with pituitary adenoma. BioMed Res. Int. 2018, https://doi.org/10.1155/2018/7490585 (2018)

27.

R. Hasanov, B.İ. Aydoğan, S. Kiremitçi, E. Erden, S. Güllü, The prognostic roles of the Ki-67 proliferation index, P53 expression, mitotic index, and radiological tumor invasion in pituitary adenomas. Endocr. Pathol. 30(1), 49–55 (2019)PubMed

28.

K. Thapar, K. Kovacs, B.W. Scheithauer, L. Stefaneanu, E. Horvath, J. Peter, P., D. Murray, E.R. Laws Jr, Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1), 99–107 (1996)PubMed

29.

L. Mastronardi, A. Guiducci, C. Spera, F. Puzzilli, F. Liberati, G. Maira, Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J. Clin. Pathol. 52(2), 107–111 (1999)PubMedPubMedCentral

30.

A.M. Landolt, T. Shibata, P. Kleihues, Growth rate of human pituitary adenomas. J. Neurosurg. 67(6), 803–806 (1987)PubMed

31.

C.P. Miermeister, S. Petersenn, M. Buchfelder, R. Fahlbusch, D.K. Lüdecke, A. Hölsken, M. Bergmann, H.U. Knappe, V.H. Hans, J. Flitsch, Histological criteria for atypical pituitary adenomas–data from the German pituitary adenoma registry suggests modifications. Acta Neuropathologica Commun. 3(1), 50 (2015)

32.

R. Gejman, B. Swearingen, E.T. Hedley-Whyte, Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum. Pathol. 39(5), 758–766 (2008)PubMed

33.

S. Ding, C. Li, S. Lin, Y. Yang, D. Liu, Y. Han, Y. Zhang, L. Li, L. Zhou, S. Kumar, Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum. Pathol. 37(7), 861–866 (2006)PubMed

34.

F. Rotondo, S. Sharma, B. Scheithauer, E. Horvath, L. Syro, M. Cusimano, F. Nassiri, G. Yousef, K. Kovacs, Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes. Neoplasma 57(6), 590 (2010)PubMed

35.

S. Vidal, K. Kovacs, E. Horvath, B.W. Scheithauer, T. Kuroki, R.V. Lloyd, Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 438(6), 595–602 (2001)PubMed

36.

C.B. Pizarro, M.C. Oliveira, J.F. Pereira‐Lima, C.G. Leães, C.K. Kramer, T. Schuch, L.M. Barbosa‐Coutinho, N.P. Ferreira, Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathology 29(1), 40–44 (2009)PubMed

37.

R.V. Lloyd, S. Vidal, E. Horvath, K. Kovacs, B. Scheithauer, Angiogenesis in normal and neoplastic pituitary tissues. Microscopy Res. Tech. 60(2), 244–250 (2003)

38.

K. Takada, S. Yamada, A. Teramoto, Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr. Pathol. 15(2), 131–139 (2004)PubMed

39.

M. Raica, M. Coculescu, A.M. Cimpean, D. Ribatti, Endocrine gland derived-VEGF is down-regulated in human pituitary adenoma. Anticancer Res. 30(10), 3981–3986 (2010)PubMed

40.

R.V. Lloyd, B.W. Scheithauer, T. Kuroki, S. Vidal, K. Kovacs, L. Stefaneanu, Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr. Pathol. 10(3), 229–235 (1999)PubMed

41.

J.M. Walz, D. Boehringer, H.L. Deissler, L. Faerber, J.C. Goepfert, P. Heiduschka, S.M. Kleeberger, A. Klettner, T.U. Krohne, N. Schneiderhan-Marra, Pre-analytical parameters affecting vascular endothelial growth factor measurement in plasma: identifying confounders. PLoS One 11(1), e0145375 (2016)PubMedPubMedCentral

42.

R. Sánchez-Ortiga, L. Sánchez-Tejada, O. Moreno-Perez, P. Riesgo, M. Niveiro, A.M.P. Alfonso, Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 16(3), 370–377 (2013)PubMed

43.

H.E. Turner, J.A. Wass, Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1(3-4), 147–151 (1999)PubMed

44.

S. Borg, K. Kerry, J. Royds, R. Battersby, T. Jones, Correlation of VEGF production with IL1α and IL6 secretion by human pituitary adenoma cells. Eur. J. Endocrinol. 152(2), 293–300 (2005)PubMed

45.

T. Iuchi, N. Saeki, K. Osato, A. Yamaura, Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochirurgica 142(12), 1345–1351 (2000)PubMed

46.

P. Lohrer, J. Gloddek, U. Hopfner, M. Losa, E. Uhl, U. Pagotto, G.K. Stalla, U. Renner, Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74(2), 95–105 (2001)PubMed

47.

N. Li, Z. Jiang, Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas. Clin. Neurol. Neurosurg. 153, 102–106 (2017)PubMed

48.

S. Fukui, H. Nawashiro, N. Otani, H. Ooigawa, A. Yano, N. Nomura, A.M. Tokumaru, T. Miyazawa, A. Ohnuki, N. Tsuzuki, H. Katoh, S. Ishihara, K. Shima, Vascular endothelial growth factor expression in pituitary adenomas. Acta. Neurochir. Suppl. 86, 519–521 (2003)PubMed

49.

Y. Kong, Z. Ren, C. Su, R. Wang, B. Xing, Expressive level of vascular endothelial growth factor in peripheral blood in patients with pituitary adenomas. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 26(2), 164–167 (2004)PubMed

50.

W. He, L. Huang, X. Shen, Y. Yang, D. Wang, Y. Yang, X. Zhu, Relationship between RSUME and HIF-1α/VEGF-A with invasion of pituitary adenoma. Gene 603, 54–60 (2017)PubMed

51.

L.-x Pan, Z.-p Chen, Y.-s Liu, J.-h Zhao, Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J. Neuro-oncol. 74(1), 71–76 (2005)

52.

A. Sav, F. Rotondo, L.V. Syro, B.W. Scheithauer, K. Kovacs, Biomarkers of pituitary neoplasms. Anticancer Res. 32(11), 4639–4654 (2012)PubMed

53.

S. Schreiber, W. Saeger, D.K. Lüdecke, Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1(3-4), 213–220 (1999)PubMed

54.

V. Sergio, H. Eva, K. Kalman, W. Bernd, R. Scheithauer, V. Llyod, K. George, Ultrastructural features of apoptosis in human pituitary adenomas. Ultrastructural Pathol. 25(2), 85–92 (2001)

55.

F. Matano, D. Yoshida, Y. Ishii, S. Tahara, A. Teramoto, A. Morita, Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J. Neuro-oncol. 117(3), 485–491 (2014)

56.

B.D. Grigoriu, F. Depontieu, A. Scherpereel, D. Gourcerol, P. Devos, T. Ouatas, J.-J. Lafitte, M.-C. Copin, A.-B. Tonnel, P. Lassalle, Endocan expression and relationship with survival in human non–small cell lung cancer. Clin. Cancer Res. 12(15), 4575–4582 (2006)PubMed

57.

S. Wang, Z. Wu, L. Wei, J. Zhang, Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma. BMC Endocr. Disord. 19(1), 90 (2019)PubMedPubMedCentral

Titel: Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness
verfasst von: Maliheh Ghadir
Mohammad E. Khamseh
Mahshid Panahi-shamsabad
Mohammad Ghorbani
Hamideh Akbari
Ali Zare Mehrjardi
Maryam Honardoost
Bahram Jafar-Mohammadi
Publikationsdatum: 12.07.2020
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02366-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Treating thyroid nodules by radiofrequency: is the delivered energy correlated with the volume reduction rate? A pilot study

Diagnosis and management of hypocalcemia

Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism

Large intrathyroidal lipoma with radioiodine uptake

Identification of novel HLA-A0201-restricted T-cell epitopes against thyroid antigens in autoimmune thyroid diseases